An educational activity provided by i3 Health has produced knowledge gains and expertise regarding the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In the United States, prostate cancer is the most common tumor type affecting men. The American Cancer Society estimated for 2022 that there will be 268,490 new cases diagnosed, with 34,500 of these cases resulting in death. Most patients with mHSPC present with relapse after local treatment, while approximately 5% of all p...

​The FDA recently added a new approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer, based on data from the ARCHES and ENZAMET trials. In this interview with i3 Health, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, discusses the approval's significance and compares the variety of options that are now available for the treatment of metastatic hormone-sensitive disease. What are the greatest challe...

The FDA has now approved enzalutamide (Xtandi®, Astellas Pharma Inc.) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Patients with mCSPC, who comprise up to 5% of US patients with prostate cancer, have metastatic disease and either have not yet received or are continuing to respond to hormone therapy. Androgen deprivation therapy (ADT) has been considered the standard of care for mCSPC. After experiencing an initial treatment response, most patients who receive ADT al...

With around 170,000 men in the United States projected to be diagnosed with prostate cancer this year, it is the most common cancer in men. Androgen therapy is usually administered for progressive disease; however, hormone-sensitive prostate cancer can develop into castration-resistant prostate cancer, signifying treatment resistance to androgen deprivation therapy or to antiandrogens. There is a lack of understanding surrounding the transition from castration-sensitive to castration-resistant a...